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ScienceDirectIL-33 is a nuclear cytokine from the IL-1 family constitutively
expressed in epithelial barrier tissues and lymphoid organs,
which plays important roles in type-2 innate immunity and
human asthma. Recent studies indicate that IL-33 induces
production of large amounts of IL-5 and IL-13 by group 2 innate
lymphoid cells (ILC2s), for initiation of allergic inflammation
shortly after exposure to allergens or infection with parasites or
viruses. IL-33 appears to function as an alarmin (alarm signal)
rapidly released from producing cells upon cellular damage or
cellular stress. In this review, we discuss the cellular sources,
mode of action and regulation of IL-33, and we highlight its
crucial roles in vivo with particular emphasis on results obtained
using IL33-deficient mice.
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Introduction
IL-33 is a nuclear cytokine, initially designated NF-HEV
[1,2], which exhibits structural similarities with IL-1
[3–6]. It activates Myd88-dependent signaling pathways
in target cells expressing the ST2/IL-1RAcP receptor
complex [3,4,6], including group 2 innate lymphoid cells
(ILC2s, natural helper cells, nuocytes, innate helper
2 cells), mast cells and their progenitors, basophils, eosi-
nophils, Th2 cells, NKT and NK cells [3,5,6]. Studies
performed over the past three years indicate that ILC2s,
which secrete huge amounts of IL-5 and IL-13 in
response to IL-33, and play crucial roles in type-2 immu-
nity, allergic inflammation and eosinophil homeostasis,
are major targets of IL-33 in vivo [7–12,13]. The purpose
of this review is to highlight the crucial role of IL-33 in
innate immunity, inflammation and allergy, and to discusswww.sciencedirect.com its mode of action as an ‘alarmin’ and the mechanisms
involved in its regulation, with particular emphasis on
recent advances and studies focused on the analysis of
endogenous IL-33.
IL-33: a crucial actor in innate immunity,
inflammation and allergy
Role in innate immune responses following infection
with parasites and viruses
IL-33 plays important roles in type-2 innate immunity.
After infection with the helminth Nippostrongylus brasi-
liensis and in response to IL-33, ILC2s expanded robustly
and produced large amounts of IL-13, which led to goblet
cell hyperplasia in the intestine and worm expulsion,
even in the absence of adaptive immunity [7–9].
IL-33-deficient mice failed to clear worms due to a se-
lective defect in ILC2-derived IL-13 [14]. Responsive-
ness of ILC2s to IL-33 was found to be controlled by Gfi1,
a transcription factor which regulates ST2 expression at
the surface of ILC2s [15]. Endogenous IL-33 has also
been shown to be important for lung eosinophilic inflam-
mation and IL-5 production by ILC2s, after infection
with the nematode Strongyloides venezuelensis or intranasal
administration of chitin, a polysaccharide constituent of
many parasites and allergens [16,17].
IL-33 is involved in the response to viral infection. For
instance, IL-33/ST2 signaling has been found to be
required for ILC2-dependent restoration of airway epi-
thelial integrity after infection with influenza virus [18].
Activation of lung ILC2s by IL-33 was also shown to
mediate influenza-induced airway hyper-reactivity inde-
pendently of adaptive immunity [19]. In addition, analysis
of parainfluenza virus infection in IL-33-deficient mice
revealed an essential role of IL-33 in induction of IL-13,
mucus overproduction and chronic lung disease following
viral infection [20]. Finally, endogenous IL-33 has been
found to be necessary for induction of potent CD8+ T cell
responses to replicating, prototypic RNA and DNA viruses
in mice [21], indicating that IL-33 may play a role in type-1
immune responses under certain conditions.
Activation of ILC2s in allergic inflammation
The crucial role of endogenous IL-33 in allergic inflam-
mation was first demonstrated using IL-33-deficient mice
[22]. IL-33 was found to be required for ovalbumin-
induced and protease allergen (papain)-induced airway
inflammation [22,23]. Further analyses revealed that IL-
33 induces allergic airway inflammation by stimulating
lung ILC2s [24–26,27]. Indeed, papain-driven IL-5Current Opinion in Immunology 2014, 31:31–37
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The IL-33/ST2-ILC2 axis and genetic susceptibility to asthma. Genetic studies suggest a major role for the IL-33/ST2 pathway in human asthma.
Indeed, IL33 and ST2 were the only two genes reproducibly identified in all major genome-wide association studies. IL-33, which is abundantly
expressed in airway epithelial cells, may initiate allergic inflammation by activating ILC2s, for production of large amounts of type-2 cytokines IL-5 and
IL-13. Interestingly, a number of genes linked to ILC2s (TSLP, RORA, IL2RB, IL13) have been identified in the genetic association studies. The capacity
of the IL-33/ST2-ILC2 axis to induce allergic inflammation, eosinophilia and goblet cell hyperplasia, may explain its central role in susceptibility to
asthma. Chromosomal localizations of IL33, ST2 and the other susceptibility genes are indicated.and IL-13 production from ILC2s, eosinophilic lung
inflammation and Th2 cell differentiation were all
found to be impaired in intranasally challenged
IL-33-deficient mice [26,27]. IL-33/ST2 signaling
was also required for IL-5 and IL-13 production by lung
ILC2s, and airway eosinophilia following exposure to
the clinically relevant fungal allergen Alternaria alter-
nata [24] or the danger signal uric acid [28].
IL-33 also appears to be important for allergic inflammation
in other tissues (nasopharynx, skin). For instance, studies
using IL-33-deficient mice have revealed the crucial role of
IL-33 in the development of experimental allergic rhinitis
induced by ragweed pollen [29]. IL-33 is a potent stimu-
lator for skin ILC2s, and the absence of IL-33 signaling
resulted in decreased skin inflammation in a mouse model
of atopic dermatitis [30]. In humans, IL-33-responsive
ILC2s have been shown to be enriched in nasal polyps of
patients with chronic rhinosinusitis [10], and in lesional
skin biopsies of atopic dermatitis patients [30].
Susceptibility to human asthma
The genes encoding IL-33 and ST2/IL1RL1 have been
identified as major susceptibility loci for human asthma in
several genome-wide association studies, which included
thousands of patients from diverse ethnic groups and
different forms of asthma (asthma associated with blood
eosinophils, early childhood asthma with severe exacer-
bations, etc.). Interestingly, IL33 and ST2/ILRL1 were
the only two genes reproducibly found to be associatedCurrent Opinion in Immunology 2014, 31:31–37 with asthma in all these studies [31–34,35]. Several other
genes important for ILC2 differentiation (RORA, tran-
scription factor RORa), proliferation (IL2RB, IL-2 re-
ceptor subunit), activation (TSLP, cytokine TSLP) and
function (IL13, type-2 cytokine IL-13) have been ident-
ified as susceptibility loci in some of these studies
[32–34]. The IL-33/ST2-ILC2 axis is thus likely to play
a crucial role in human asthma (Figure 1).
IL-33: a tissue-derived nuclear cytokine
Constitutive expression in epithelial barrier tissues and
lymphoid organs
An important characteristic of IL-33 is the fact that it is
constitutively expressed to high levels in human and
mouse tissues during homeostasis [36,37]. Indeed, abun-
dant expression of the endogenous IL-33 protein has been
observed in epithelial cells from tissues exposed to the
environment, and in fibroblastic reticular cells (FRCs) of
lymphoid organs (Table 1) [36,37]. High levels of IL-33
were also detected in endothelial cells from blood vessels
in human tissues [2,36], but not in mouse [37].
Strikingly, the endogenous IL-33 protein was always
localized in the nucleus of producing cells in both human
and mouse tissues [36,37], with no evidence for cyto-
plasmic or extracellular localization, indicating that IL-33
is a nuclear cytokine in vivo. Although its nuclear roles
remain unclear, IL-33 can associate with chromatin by
tethering to histones H2A/H2B, via a short chromatin-
binding motif, located in its N-terminal nuclear domainwww.sciencedirect.com
IL-33 and allergic inflammation Cayrol and Girard 33
Table 1
Major sources of IL-33 protein in human and mouse tissues
Humana Mousea,b
Epithelial barrier tissues
Lung Airway epithelium Alveolar type II
epithelium
Skin Keratinocytes Keratinocytes
Stomach Simple cuboı¨dal
epithelium
Simple cuboı¨dal
epithelium
Salivary glands Stratified cuboı¨dal
epithelium
Stratified cuboı¨dal
epithelium
Lymphoı¨d organs
Lymph nodes Fibroblastic reticular
cells,
Fibroblastic reticular
cells
(Tonsil, appendix) HEV endothelium –
Spleen Fibroblastic reticular
cells
Fibroblastic reticular
cells
Vascular tree
Blood vessels Endothelium –
a Endogenous IL-33 protein was always localized in the nucleus of
producing cells.
b Expression of IL-33 protein was correlated to the activity of the IL33
promoter visualized using an IL33-LacZ reporter strain.[2,38]. Deletion of this chromatin-binding nuclear
domain has recently been shown to result in constitutive
extracellular release of the protein, ST2-dependent
multi-organ inflammation and death of the organism
[39]. Nuclear localization (retention) is thus a funda-
mental property of IL-33, which is crucial for regulation of
its cytokine activity.
Inducible expression during inflammation
Although IL-33 is constitutively expressed in tissues
under basal conditions, its expression can be further
increased during inflammation. For instance, induction
of IL33 promoter activity and upregulation of IL-33
protein levels were observed in alveolar type II (ATII)
pneumocytes upon allergic lung inflammation following
exposure to ovalbumin, ragweed pollen or Alternaria
[25,40]. Upregulation of nuclear IL-33 in mouse ATII
cells has also been detected upon lung eosinophilic
inflammation induced by intestinal nematode infection,
and after intranasal administration of chitin [16]. In
humans, increased expression of IL-33 in the nuclei of
airway epithelial cells has been reported in patients with
asthma [41] and chronic obstructive pulmonary disease
(COPD) [20]. Interestingly, IL-33 expression was trace-
able to a subset of airway epithelial cells with progenitor
function [20]. Inducible expression of IL-33 in mouse
tissues has also been observed outside the lungs, for instance
in hepatocytes during acute hepatitis [42], and in endothelial
cells from the inflamed colon during colitis [37].
IL-33 is generally not expressed in CD45+ hematopoietic
cells under basal conditions, but it can be induced in
macrophages and dendritic cells during allergic inflam-
mation and infection [19,40,43]. However, IL-33 levelswww.sciencedirect.com in CD45+ cells appear to be at least 10 fold lower than those
found in CD45 epithelial cells [20,25,40], and the
protein was not detected in F4/80+ alveolar macrophages
in lung tissue sections during allergic inflammation [23] or
infection [16]. In addition, recent analyses in a mouse
model of allergic rhinitis revealed that tissue-derived
IL-33, rather than immune-cell derived IL-33, is crucial
for induction of allergic inflammation [44].
IL-33: an alarmin released upon cellular stress
and injury
Mode of action as an alarmin
Biologically active full length IL-33 can be released in the
extracellular space after cell damage (necrotic cell death)
or mechanical injury [45,46]. IL-33 was thus proposed to
function as a novel alarmin (intracellular alarm signal
released upon cell injury) to alert the immune system
of tissue damage following trauma or infection
[36,37,45,46]. IL-33 is likely to be a very good alarm
signal because, due to its constitutive expression in
normal tissues, it is ready to be released at any time,
for ‘alarming’ ILC2s and other immune cells (Figure 2).
Environmental allergens, such as ragweed pollen and A.
alternata, have been shown to induce the rapid (1 hour)
release of IL-33 in nasal and bronchoalveolar lavage
(BAL) fluids, respectively [29,47,48]. This increase of
IL-33 protein in extracellular fluids was associated with
reduced staining for IL-33 in the nuclei of nasal epithelial
cells [29] and ATII pneumocytes [48], suggesting extra-
cellular release of preformed nuclear IL-33. Many air-
borne allergens have intrinsic protease activities
[26,28,48], and allergen proteases have been shown to
play a role in the rapid increase of IL-33 levels in BAL
fluids after intranasal administration [26,48]. Allergens
and allergen proteases can cause breakdown of epithelial
barriers in vivo and may thus induce the release of IL-33
through cellular necrosis. However, allergen exposure
also leads to extracellular accumulation of danger signals,
such as ATP and uric acid, which appear to induce the
extracellular release of IL-33 without apparent cell death
[20,28,47]. ATP is known to be released in various
noncytolytic conditions, including membrane defor-
mations, mechanical stress or osmotic stress [47]. Cellular
stress, in addition to cellular necrosis, may thus turn out to
be an important mechanism for IL-33 release in vivo.
Regulation by proteases
Proteases have been shown to regulate IL-33 activity
(Figure 2). IL-33 contains a consensus site of cleavage
for caspase-3 (DGVD178G in human), and cleavage by
caspases at this site generates two biologically inactive
products [45,46]. Inactivation of IL-33 during apoptosis is
likely to be important to avoid alerting the immune
system unnecessarily after physiological programmed
(apoptotic) cell death, as opposed to pathological (necro-
tic) cell death [45,46].Current Opinion in Immunology 2014, 31:31–37
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IL-33, a tissue-derived nuclear alarmin. During homeostasis, nuclear IL-33 is constitutively expressed to high levels in epithelial barrier tissues,
such as the lung, skin and stomach. Full length bioactive IL-33 is released extracellularly upon tissue damage and cell death (or cellular stress),
following exposure to allergens or infection with viruses or parasites. After release, IL-33 ‘raises the alarm’ in the immune system by activating
various types of immune cells, including mast cells and, most importantly, ILC2s, which secrete large amounts of IL-5 and IL-13. After
programmed cell death (apoptosis), IL-33 is inactivated by caspases to avoid alerting the immune system unnecessarily. Although full length
IL-33 is active, it can be processed by inflammatory proteases (cathepsin G, elastase) into shorter ‘hyperactive’ mature forms, which may be the
crucial bioactive forms in vivo.
Current Opinion in Immunology 2014, 31:31–37 www.sciencedirect.com
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released during inflammation appear to increase IL-33
biological activity [49]. Neutrophil serine proteases,
cathepsin G and elastase, were found to process full
length IL-33 into mature forms containing the IL-1-like
cytokine domain (IL-3395–270, IL-3399–270 and IL-33109–
270), that had greatly increased biological activity (10
fold) compared to the full length protein [49]. Both full
length and mature endogenous IL-33 were detected in
BAL fluids in a model of acute lung injury associated with
high levels of neutrophil recruitment in the alveolar wall
[49]. Together, these results suggested that proteolytic
processing of IL-33 may be required for the extracellular
generation of highly active cytokine in vivo.
Conclusions and future directions
IL-33 is an alarmin cytokine from the IL-1 family, which
plays a crucial role in the initiation of type-2 immune
responses following infection with parasites or viruses, or
exposure to allergens. IL-33 appears to act by activating
ILC2s for production of large amounts of type-2 cytokines
IL-5 and IL-13. The potent activity of IL-33 on ILC2s
and the crucial role of these cells in the initiation of
allergic airway inflammation are likely to explain the
dominant role of the IL-33/ST2 pathway in genetic
susceptibility to human asthma. Despite these important
advances, many questions remain to be answered. For
instance, the potential redundancy or synergy of IL-33
with other activators of ILC2s, that have been recently
identified (Prostaglandin D2, Leukotriene D4, IL-9,
etc.), needs to be studied. Although the functions of
IL-33 in the activation of ILC2s and the initiation of
allergic inflammation in the lungs have been well estab-
lished, its roles in allergic and non-allergic inflammation
in other tissues, exhibiting high expression levels of the
endogenous protein, remain to be fully explored. A better
understanding of IL-33 release, mode of action and
regulation will be crucial for the development of thera-
peutics that target the IL-33/ST2 pathway to treat asthma
and other inflammatory diseases.
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